Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Millennium Pharmacon International Tbk (ISX:SDPC) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
PT Millennium Pharmacon International Tbk Equity-to-Asset Related Terms
PT Millennium Pharmacon International Tbk Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Millennium Pharmacon International Tbk Equity-to-Asset Chart
PT Millennium Pharmacon International Tbk Annual Data
ISX:SDPC vs MCK, COR, CAH: Equity-to-Asset Comparison
For the Medical Distribution subindustry, PT Millennium Pharmacon International Tbk's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Millennium Pharmacon International Tbk Equity-to-Asset vs Medical Distribution Industry
PT Millennium Pharmacon International Tbk Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Millennium Pharmacon International Tbk (ISX:SDPC) has a Equity-to-Asset of 0.16 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on PT Millennium Pharmacon International Tbk and its competitors. This is 16% below median its historical median of 0.19. Over the past decade, PT Millennium Pharmacon International Tbk's Equity-to-Asset has ranged from 0.15 to 0.24. According to the industry distribution chart, PT Millennium Pharmacon International Tbk ranks #105 out of 120 companies in the Medical Distribution industry, placing it in the top 87.5%.
Is PT Millennium Pharmacon International Tbk's Equity-to-Asset too high?
PT Millennium Pharmacon International Tbk's current Equity-to-Asset of 0.16 is 16% below median its 10-year median of 0.19. Over the past 10 years, this metric has ranged from a low of 0.15 to a high of 0.24. The Medical Distribution industry median Equity-to-Asset is 0.39. PT Millennium Pharmacon International Tbk's value of 0.16 is 59% below this industry median. Based on the distribution chart, PT Millennium Pharmacon International Tbk ranks #105 out of 120 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, PT Millennium Pharmacon International Tbk has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PT Millennium Pharmacon International Tbk's Equity-to-Asset compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Millennium Pharmacon International Tbk ranks #105 out of 120 companies for Equity-to-Asset. This places PT Millennium Pharmacon International Tbk in the lower half of its industry. The industry median Equity-to-Asset is 0.39. PT Millennium Pharmacon International Tbk's value of 0.16 is 59% below this benchmark. Historically, PT Millennium Pharmacon International Tbk's own Equity-to-Asset has ranged from 0.15 to 0.24 over the past decade. While the company's 10-year median is 0.19 vs. the industry median of 0.39, PT Millennium Pharmacon International Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Distribution company?
The median Equity-to-Asset among Medical Distribution companies is 0.39, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Millennium Pharmacon International Tbk's current Equity-to-Asset of 0.16 is 59% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on PT Millennium Pharmacon International Tbk and its competitors. For the Medical Distribution industry, the median Equity-to-Asset is 0.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Millennium Pharmacon International Tbk's current Equity-to-Asset is 0.16, which is 16% below median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Millennium Pharmacon International Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk (ISX:SDPC) is currently considered Modestly Overvalued. The stock's GF Value™ is Rp170.14, compared to a current price of Rp192.00 — trading 12.8% above its estimated fair value. The current Equity-to-Asset is 0.16, which is 16% below median its 10-year median of 0.19 and 59% below the Medical Distribution industry median of 0.39. PT Millennium Pharmacon International Tbk's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For PT Millennium Pharmacon International Tbk (ISX:SDPC), the current Equity-to-Asset is 0.16 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Millennium Pharmacon International Tbk (ISX:SDPC) Overvalued in 2026?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk stock appears to be overvalued.
The current stock price of Rp192.00 is trading 12.8% above its estimated GF Value™ of Rp170.14.
GuruFocus considers PT Millennium Pharmacon International Tbk to be Modestly Overvalued.
Key valuation signals for ISX:SDPC:
Equity-to-Asset: 0.16 (16% below median its 10-year median of 0.19)
GF Value™: Rp170.14 vs. price of Rp192.00 (12.8% above fair value)
Industry Position: 59% below the Medical Distribution median (#105 of 120)
No single metric tells the full story. See the ISX:SDPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressJl. Sultan Iskandar Muda No 18/Jl. Bungur No. 1, Crown Bungur Arteri Lantai 2-4, Kel. Kebayoran Lama Selatan, Kec. Kebayoran Lama, South Jakarta, Jakarta, IDN, 12240
PT Millennium Pharmacon International Tbk is engaged in distributing medicines, food supplements, and medical disposables. The group's operating segments are Prescription medicine, Non-prescription medicine, Medical Disposables, and others, of which the majority of revenue is derived from the Prescription Medicine segment. The company's geographical segments are Jawa, Sumatra, Kalimantan, Sulawesi, and Bali & Lombok.
78GF Score
Get the complete analysis for ISX:SDPC
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SDPC has been successfully added to your 
